DIFFICULTY IN ERADICATING HELICOBACTER-PYLORI IN A POPULATION AT HIGH-RISK FOR STOMACH-CANCER IN VENEZUELA

被引：32

作者：

BUIATTI, E ^{[1
]}

MUNOZ, N ^{[1
]}

VIVAS, J ^{[1
]}

CANO, E ^{[1
]}

PERAZA, S ^{[1
]}

CARILLO, E ^{[1
]}

CASTRO, D ^{[1
]}

SANCHEZ, V ^{[1
]}

ANDRADE, O ^{[1
]}

BENZ, M ^{[1
]}

DESANJOSE, S ^{[1
]}

OLIVER, W ^{[1
]}

机构：

[1] INSURANCE INST HIGHWAY SAFETY,150 COURS ALBERT THOMAS,WASHINGTON,DC 20037

来源：

CANCER CAUSES & CONTROL | 1994年 / 5卷 / 03期

关键词：

AMOXICILLIN; BISMUTH; ERADICATION; HELICOBACTER-PYLORI; STOMACH CANCER; VENEZUELA;

D O I：

10.1007/BF01830244

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The bacterium Helicobacter pylori (HP) has been implicated in the etiology of precancerous lesions of the stomach and there is evidence suggesting that it may influence the efficacy of chemoprevention of gastric cancer with vitamin C. Eradication seldom has been attempted in populations from developing countries, with a high prevalence of HP frequently resistant to metronidazole. A randomized, double-blind, controlled trial to evaluate the efficacy of colloidal bismuth subcitrate (120 mg q.i.d.) and amoxycillin (500 mg q.i.d.) in eradicating HP was conducted in 220 subjects drawn from a population with a high prevalence of metronidazole-resistant HP in Tachira state, Venezuela. One month after completion of two weeks' treatment, eradication rates of 6.5 percent in the treatment group and two percent in the placebo group were estimated on the basis of HP diagnosis in biopsies, and of 13.9 percent compared with 3.9 percent on the basis of a C-14-urea breath test, although the negative predictive value of the breath test was very low compared with HP diagnosis in biopsies. In the treatment group, particularly among males, a significant decrease in bacterial load was detected. Reasons for failure of treatment in high HP-prevalence areas are discussed, and it is suggested that primary prevention of HP infection may be the optimal approach to reducing levels of stomach cancer in these high-risk groups.

引用

页码：249 / 254

页数：6

共 14 条

[1]

Forman D., Newell D.G., Fullerton F., Et al., Association between infection with Helicobacter pylori and risk of gastric cancer

[2]

evidence from a prospective investigation, Br Med J, 302, pp. 1302-5, (1991)

[3]

Parsonnet J., Friedman G.D., Vandersteen D.P., Et al., Helicobacter pylori infection and the risk of gastric carcinoma, N Engl J Med, 325, pp. 1127-31, (1991)

[4]

Nomura A., Stemmerman G.N., Chyou P.H., Kato I., Perez-Perez I., Blaser M.J., Helicobacter pylori infection and gastric carcinoma among. Japanese Americans in Hawaii, N Engl J Med, 325, pp. 1132-6, (1991)

[5]

Megraud F., Epidemiology of Helicobacter pylori infection, Gastroenterol Clin North Am, 22, pp. 73-88, (1993)

[6]

Sobala G.M., Grabtree J., Dixon M.F., Et al., Acute Helicobacter pylori infection: clinical features, local and systemic immune response, gastric mucosal histology and gastric juice ascorbic acid concentrations, Gut, 32, pp. 1415-8, (1991)

[7]

Axon A.T.R., Campylobacter pylori—therapy review, Scand J Gastroenterol, 24, pp. 35-8, (1989)

[8]

Axon A.T.R., Helicobacter pylori therapy—effect of peptic ulcer disease, J Gastroenterol Hepatol, 6, pp. 131-7, (1989)

[9]

Peraza S., Castro D., Oliver W.E., Et al., Investigation histologica de Helicobacter pylori en 265 biopsias gastricas consecutivas, GEN, 45, pp. 163-6, (1991)

[10]

Munoz N., Oliver W., Sobala G.M., Et al., Prevalence of Helicobacter pylori infection and effect of antioxidants in a high risk population for gastric cancer in Venezuela, Ital J Gastroenterol, 23, (1991)

← 1 2 →